Firms focused on future development and commercialization of facial aesthetics pipeline.
Genzyme will develop future hyaluronic acid (HA) dermal filler products according to a commercialization agreement with Mentor.
The first product launch under the agreement is scheduled to occur internationally in early 2007, with a worldwide launch of an additional product in late 2007.
Genzyme and Mentor will join resources to develop a longer-lasting HA dermal filler. With Genzyme’s history in HA development and manufacturing, Mentor has created a partnership that will allow its facial aesthetics pipeline to expand significantly. All the products will be introduced into Mentor’s current distribution network, maximizing the revenue opportunity.
